FDA Brief

Warning letters Drugs

FDA warning letter to

Kilitch Healthcare India Limited

High riskIssued Mar 28, 2024Posted Apr 9, 2024Center for Drug Evaluation and Research | CDER

FDA warns Kilitch Healthcare India over insanitary sterile drug manufacturing and falsified environmental monitoring data.

What happened

FDA inspected Kilitch Healthcare India's Navi Mumbai drug manufacturing facility from October 12 to October 20, 2023. Investigators found insanitary conditions, poor aseptic practices, inadequate media fills and smoke studies, and facility disrepair. FDA also found that laboratory staff fabricated or altered environmental monitoring results and completed batch records months late.

What FDA found

  1. FDA found the facility in disrepair and poorly cleaned, with barefoot employees lacking required gowning and gloves and dirty RABS parts used on the filling line.

    FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)
  2. The firm failed to follow adequate written procedures to prevent microbial contamination in sterile drug production, with poor aseptic behaviors and media fills and smoke studies that did not simulate actual manufacturing.

    21 CFR 211.113(b)
  3. Laboratory records were incomplete or falsified, including fabricated environmental monitoring results and batch records completed months after manufacture.

    21 CFR 211.194(a)
  4. Environmental monitoring lacked scientific justification and used inadequate media and plates, while facility maintenance gaps risked contamination of aseptic areas.

    21 CFR 211.42(c)(10)
  5. The quality unit failed its oversight duties, including releasing batches before process validation, supporting expiration dates with limited stability data, and not adequately sampling for DEG and EG.

    21 CFR 211.22

What FDA wants

FDA directs Kilitch to respond with comprehensive remediation plans and independent assessments covering aseptic practices, contamination hazards, laboratory and data integrity, environmental monitoring, and quality-unit oversight. The provided letter does not state a response deadline.

Who should pay attention

  • brands that buy finished sterile eye drops from this contract manufacturer
  • distributors and retailers selling Equate eye drops
  • companies relying on environmental monitoring or data integrity at sterile drug suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk